1454P PARAFIRIGAST: Paclitaxel/ramucirumab versus FOLFIRI as second line chemotherapy of metastatic gastric cancer: An AGEO multicenter comparative study with a propensity score analysis

Authors :: A. Pellat
C. Toullec
M. Kroemer
David Tougeron
J. Vivier-Chicoteau
J. Lavole
B. De Rauglaudre
Astrid Pozet
Gael Goujon
David Sefrioui
Yann Touchefeu
Vincent Hautefeuille
A.L. Bignon Bretagne
Carole Vitellius
J. Wasselin
Anthony Turpin
O. Bouche
A. Zaanan
S. Racine Doat
Cristina Smolenschi
Source :: Annals of Oncology. 31:S912-S913
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Hematology
Second line chemotherapy
Metastatic gastric cancer
Ramucirumab
chemistry.chemical_compound
Paclitaxel
chemistry
Internal medicine
Propensity score matching
medicine
FOLFIRI
business

Full Text Access

Tools